The importance of first impressions: Early events in mycobacterium tuberculosis infection influence outcome

mBio

Volumn 7, Issue 2, 2016, Pages

  Cadena, Anthony M ^a   Flynn, Joanne L ^a   Fortune, Sarah M ^b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BETA INTERFERON; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CXCL2 CHEMOKINE; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; LIPOXIN A; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MICRORNA 223; PROSTAGLANDIN E2; T LYMPHOCYTE RECEPTOR; TUBERCULIN; TUMOR NECROSIS FACTOR; BCG VACCINE;

BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL EXPANSION; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GRANULOMA; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LUNG LAVAGE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUBERCULIN TEST; TUBERCULOSIS; ANIMAL; GENETICS; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84965125893     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00342-16     Document Type: Review

References (91)

1. WHO. 2015. Global tuberculosis report 2015. WHO, Geneva, Switzerland. http://www.who.int/tb/publications/global_report/en/.
2. Barry CE, III, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7:845–855. http://dx.doi.org/10.1038/nrmicro2236.
3. Lin PL, Flynn JL. 2010. Understanding latent tuberculosis: a moving target. J Immunol 185:15–22. http://dx.doi.org/10.4049/jimmunol.0903856.
4. Coleman MT, Maiello P, Tomko J, Frye LJ, Fillmore D, Janssen C, Klein E, Lin PL. 2014. Early changes by (18)fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 82:2400–2404. http://dx.doi.org/10.1128/IAI.01599-13.
5. Poulsen A. 1950. Some clinical features of tuberculosis. 1. Incubation period. Acta Tuberc Scand 24:311–346.
6. Weldingh K, Andersen P. 2008. ESAT-6/CFP10 skin test predicts disease in M. tuberculosis-infected guinea pigs. PLoS One 3:e1978. http://dx.doi.org/10.1371/journal.pone.0001978.
7. Capuano SV, III, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, Bissel S, Fuhrman C, Klein E, Flynn JL. 2003. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 71:5831–5844. http://dx.doi.org/10.1128/IAI.71.10.5831-5844.2003.
8. Pelletier M, Forget A, Bourassa D, Skamene E. 1984. Histological and immunopathological studies of delayed hypersensitivity reaction to tuberculin in mice. Infect Immun 46:873–875.
9. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, Ernst JD. 2008. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 205:105–115. http://dx.doi.org/10.1084/jem.20071367.
10. Poulsen A. 1957. Some clinical features of tuberculosis. Acta Tuberc Scand 33:37–92.
11. Gedde-Dahl T. 1952. Tuberculous infection in the light of tuberculin matriculation. Am J Hyg 56:139–214.
12. Shapiro AE, Variava E, Rakgokong MH, Moodley N, Luke B, Salimi S, Chaisson RE, Golub JE, Martinson NA. 2012. Community-based targeted case finding for tuberculosis and HIV in household contacts of patients with tuberculosis in South Africa. Am J Respir Crit Care Med 185: 1110–1116. http://dx.doi.org/10.1164/rccm.201111-1941OC.
13. Marais BJ, Obihara CC, Gie RP, Schaaf HS, Hesseling AC, Lombard C, Enarson D, Bateman E, Beyers N. 2005. The prevalence of symptoms associated with pulmonary tuberculosis in randomly selected children from a high burden community. Arch Dis Child 90:1166–1170. http://dx.doi.org/10.1136/adc.2004.060640.
14. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, Chiosea I, Capuano SV, Fuhrman C, Klein E, Flynn JL. 2009. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 77:4631–4642. http://dx.doi.org/10.1128/IAI.00592-09.
15. Lin PL, Coleman T, Carney JPJ, Lopresti BJ, Tomko J, Fillmore D, Dartois V, Scanga C, Frye LJ, Janssen C, Klein E, Barry CE, III, Flynn JL. 2013. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother 57: 4237–4244. http://dx.doi.org/10.1128/AAC.00277-13.
16. Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, Sacchettini J, Fortune SM, Flynn JL. 2014. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 20:75–79. http://dx.doi.org/10.1038/nm.3412.
17. Canetti G. 1955. The tubercle bacillus. Springer Publishing Co., Inc., New York, NY.
18. Turner OC, Basaraba RJ, Orme IM. 2003. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun 71:864–871. http://dx.doi.org/10.1128/IAI.71.2.864-871.2003.
19. Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, Reinhart TA, Capuano SV, Klein E, Flynn JL. 2006. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 74:3790–3803. http://dx.doi.org/10.1128/IAI.00064-06.
20. Davis JM, Ramakrishnan L. 2009. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136:37–49. http://dx.doi.org/10.1016/j.cell.2008.11.014.
21. Ramakrishnan L. 2012. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12:352–366. http://dx.doi.org/10.1038/nri3211.
22. Chen M, Divangahi M, Gan H, Shin DS, Hong S, Lee DM, Serhan CN, Behar SM, Remold HG. 2008. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 205:2791–2801. http://dx.doi.org/10.1084/jem.20080767.
23. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. 2010. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol 11:751–758. http://dx.doi.org/10.1038/ni.1904.
24. Elkington P, Shiomi T, Breen R, Nuttall RK, Ugarte-Gil CA, Walker NF, Saraiva L, Pedersen B, Mauri F, Lipman M, Edwards DR, Robertson BD, D’Armiento J, Friedland JS. 2011. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest 121: 1827–1833. http://dx.doi.org/10.1172/JCI45666.
25. Al Shammari B, Shiomi T, Tezera L, Bielecka MK, Workman V, Sathyamoorthy T, Mauri F, Jayasinghe SN, Robertson BD, D’Armiento J, Friedland JS, Elkington PT. 2015. The extracellular matrix regulates granuloma necrosis in tuberculosis. J Infect Dis 212:463–473. http://dx.doi.org/10.1093/infdis/jiv076.
26. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. 2010. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327:466–469. http://dx.doi.org/10.1126/science.1179663.
27. Dannenberg AM, Jr. 1989. Immune mechanisms in the pathogenesis of pulmonary tuberculosis. Rev Infect Dis 11(Suppl 2):S369–S378. http://dx.doi.org/10.1093/clinids/11.Supplement_2.S369.
28. Flynn JL, Chan J. 2001. Immunology of tuberculosis. Annu Rev Immunol 19:93–129. http://dx.doi.org/10.1146/annurev.immunol.19.1.93.
29. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. 2013. The immune response in tuberculosis. Annu Rev Immunol 31:475–527. http://dx.doi.org/10.1146/annurev-immunol-032712-095939.
30. Clay H, Davis JM, Beery D, Huttenlocher A, Lyons SE, Ramakrishnan L. 2007. Dichotomous role of the macrophage in early Mycobacterium marinum infection of the zebrafish. Cell Host Microbe 2:29–39. http://dx.doi.org/10.1016/j.chom.2007.06.004.
31. Wolf AJ, Linas B, Trevejo-Nuñez GJ, Kincaid E, Tamura T, Takatsu K, Ernst JD. 2007. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 179: 2509–2519. http://dx.doi.org/10.4049/jimmunol.179.4.2509.
32. Humphreys IR, Stewart GR, Turner DJ, Patel J, Karamanou D, Snelgrove RJ, Young DB. 2006. A role for dendritic cells in the dissemination of mycobacterial infection. Microbes Infect 8:1339–1346. http://dx.doi.org/10.1016/j.micinf.2005.12.023.
33. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, Koch C, Tufariello J, Flynn J, Chan J. 2006. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 8:218–232. http://dx.doi.org/10.1111/j.1462-5822.2005.00612.x.
34. Srivastava S, Ernst JD, Desvignes L. 2014. Beyond macrophages: the diversity of mononuclear cells in tuberculosis. Immunol Rev 262: 179–192. http://dx.doi.org/10.1111/imr.12217.
35. Matty MA, Roca FJ, Cronan MR, Tobin DM. 2015. Adventures within the speckled band: heterogeneity, angiogenesis, and balanced inflammation in the tuberculous granuloma. Immunol Rev 264:276–287. http://dx.doi.org/10.1111/imr.12273.
36. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O’Garra A. 2010. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466:973–977. http://dx.doi.org/10.1038/nature09247.
37. Bloom CI, Graham CM, Berry MP, Rozakeas F, Redford PS, Wang Y, Xu Z, Wilkinson KA, Wilkinson RJ, Kendrick Y, Devouassoux G, Ferry T, Miyara M, Bouvry D, Valeyre D, Gorochov G, Blankenship D, Saadatian M, Vanhems P, Beynon H, Vancheeswaran R, Wickremasinghe M, Chaussabel D, Banchereau J, Pascual V, Ho LP, Lipman M, O’Garra A. 2013. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 8:e70630. http://dx.doi.org/10.1371/journal.pone.0070630.
38. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, Hwang SH, Cho SN, Via LE, Barry CE, III. 2010. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137:122–128. http://dx.doi.org/10.1378/chest.09-0903.
39. Dorhoi A, Iannaccone M, Farinacci M, Faé KC, Schreiber J, Moura- Alves P, Nouailles G, Mollenkopf HJ, Oberbeck-Müller D, Jörg S, Heinemann E, Hahnke K, Löwe D, Del Nonno F, Goletti D, Capparelli R, Kaufmann SH. 2013. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest 123: 4836–4848. http://dx.doi.org/10.1172/JCI67604.
40. Yang CT, Cambier CJ, Davis JM, Hall CJ, Crosier PS, Ramakrishnan L. 2012. Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria phagocytosed from infected macrophages. Cell Host Microbe 12:301–312. http://dx.doi.org/10.1016/j.chom.2012.07.009.
41. +T cells during Mycobacterium tuberculosis infection. J Immunol 186:7110–7119. http://dx.doi.org/10.4049/jimmunol.1100001.
42. Lowe DM, Redford PS, Wilkinson RJ, O’Garra A, Martineau AR. 2012. Neutrophils in tuberculosis: friend or foe? Trends Immunol 33:14–25. http://dx.doi.org/10.1016/j.it.2011.10.003.
43. Martineau AR, Newton SM, Wilkinson KA, Kampmann B, Hall BM, Nawroly N, Packe GE, Davidson RN, Griffiths CJ, Wilkinson RJ. 2007. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 117:1988–1994. http://dx.doi.org/10.1172/JCI31097.
44. Nandi B, Behar SM. 2011. Regulation of neutrophils by interferongamma limits lung inflammation during tuberculosis infection. J Exp Med 208:2251–2262. http://dx.doi.org/10.1084/jem.20110919.
45. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, Derrick SC, Shi R, Kumar NP, Wei W, Yuan X, Zhang G, Cai Y, Babu S, Catalfamo M, Salazar AM, Via LE, Barry CE, III, Sher A. 2014. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511:99–103. http://dx.doi.org/10.1038/nature13489.
46. Bannenberg G, Serhan CN. 2010. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 1801: 1260–1273. http://dx.doi.org/10.1016/j.bbalip.2010.08.002.
47. Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, Ko DC, Zou Y, Bang ND, Chau TT, Vary JC, Hawn TR, Dunstan SJ, Farrar JJ, Thwaites GE, King MC, Serhan CN, Ramakrishnan L. 2012. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148:434–446. http://dx.doi.org/10.1016/j.cell.2011.12.023.
48. Tobin DM, Vary JC, Jr., Ray JP, Walsh GS, Dunstan SJ, Bang ND, Hagge DA, Khadge S, King MC, Hawn TR, Moens CB, Ramakrishnan L. 2010. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140:717–730. http://dx.doi.org/10.1016/j.cell.2010.02.013.
49. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. 2002. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 70: 4501–4509. http://dx.doi.org/10.1128/IAI.70.8.4501-4509.2002.
50. Myers AJ, Marino S, Kirschner DE, Flynn JL. 2013. Inoculation dose of Mycobacterium tuberculosis does not influence priming of T cell responses in lymph nodes. J Immunol 190:4707–4716. http://dx.doi.org/10.4049/jimmunol.1203465.
51. Bhatt K, Hickman SP, Salgame P. 2004. Cutting edge: a new approach to modeling early lung immunity in murine tuberculosis. J Immunol 172: 2748–2751. http://dx.doi.org/10.4049/jimmunol.172.5.2748.
52. +inflammatory monocytes during Mycobacterium tuberculosis-specific T cell priming. Elife 2:e01086. http://dx.doi.org/10.7554/eLife.01086.
53. Day TA, Koch M, Nouailles G, Jacobsen M, Kosmiadi GA, Miekley D, Kuhlmann S, Jörg S, Gamradt P, Mollenkopf HJ, Hurwitz R, Reece ST, Kaufmann SH, Kursar M. 2010. Secondary lymphoid organs are dispensable for the development of T-cell-mediated immunity during tuberculosis. Eur J Immunol 40:1663–1673. http://dx.doi.org/10.1002/eji.201040299.
54. Harding JS, Rayasam A, Schreiber HA, Fabry Z, Sandor M. 2015. Mycobacterium-infected dendritic cells disseminate granulomatous inflammation. Sci Rep 5:15248. http://dx.doi.org/10.1038/srep15248.
55. Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, Sassetti CM. 2013. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol 14:52–60. http://dx.doi.org/10.1038/ni.2474.
56. Napier RJ, Adams EJ, Gold MC, Lewinsohn DM. 2015. The role of mucosal associated invariant T cells in antimicrobial immunity. Front Immunol 6:344. http://dx.doi.org/10.3389/fimmu.2015.00344.
57. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, Williamson NA, Purcell AW, Dudek NL, McConville MJ, O’Hair RA, Khairallah GN, Godfrey DI, Fairlie DP, Rossjohn J, McCluskey J. 2012. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491:717–723. http://dx.doi.org/10.1038/nature11605.
58. Gold MC, McLaren JE, Reistetter JA, Smyk-Pearson S, Ladell K, Swarbrick GM, Yu YY, Hansen TH, Lund O, Nielsen M, Gerritsen B, Kesmir C, Miles JJ, Lewinsohn DA, Price DA, Lewinsohn DM. 2014. MR1- restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J Exp Med 211:1601–1610. http://dx.doi.org/10.1084/jem.20140507.
59. Gold MC, Napier RJ, Lewinsohn DM. 2015. MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis. Immunol Rev 264:154–166. http://dx.doi.org/10.1111/imr.12271.
60. Sia JK, Georgieva M, Rengarajan J. 2015. Innate immune defenses in human tuberculosis: an overview of the interactions between Mycobacterium tuberculosis and innate immune cells. J Immunol Res 2015:747543. http://dx.doi.org/10.1155/2015/747543.
61. Portevin D, Via LE, Eum S, Young D. 2012. Natural killer cells are recruited during pulmonary tuberculosis and their ex vivo responses to mycobacteria vary between healthy human donors in association with KIR haplotype. Cell Microbiol 14:1734–1744. http://dx.doi.org/10.1111/j.1462-5822.2012.01834.x.
62. Hall-Stoodley L, Watts G, Crowther JE, Balagopal A, Torrelles JB, Robison-Cox J, Bargatze RF, Harmsen AG, Crouch EC, Schlesinger LS. 2006. Mycobacterium tuberculosis binding to human surfactant proteins A and D, fibronectin, and small airway epithelial cells under shear conditions. Infect Immun 74:3587–3596. http://dx.doi.org/10.1128/IAI.01644-05.
63. Beharka AA, Gaynor CD, Kang BK, Voelker DR, McCormack FX, Schlesinger LS. 2002. Pulmonary surfactant protein A up-regulates activity of the mannose receptor, a pattern recognition receptor expressed on human macrophages. J Immunol 169:3565–3573. http://dx.doi.org/10.4049/jimmunol.169.7.3565.
64. Gold JA, Hoshino Y, Tanaka N, Rom WN, Raju B, Condos R, Weiden MD. 2004. Surfactant protein A modulates the inflammatory response in macrophages during tuberculosis. Infect Immun 72:645–650. http://dx.doi.org/10.1128/IAI.72.2.645-650.2004.
65. Ferguson JS, Voelker DR, McCormack FX, Schlesinger LS. 1999. Surfactant protein D binds to Mycobacterium tuberculosis bacilli and lipoarabinomannan via carbohydrate-lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages. J Immunol 163:312–321.
66. Lemos MP, McKinney J, Rhee KY. 2011. Dispensability of surfactant proteins A and D in immune control of Mycobacterium tuberculosis infection following aerosol challenge of mice. Infect Immun 79:1077–1085. http://dx.doi.org/10.1128/IAI.00286-10.
67. Cakir E, Torun E, Gedik AH, Umutoglu T, Aktas EC, Topuz U, Deniz G. 2014. Cathelicidin and human beta-defensin 2 in bronchoalveolar lavage fluid of children with pulmonary tuberculosis. Int J Tuberc Lung Dis 18:671–675. http://dx.doi.org/10.5588/ijtld.13.0831.
68. Sonawane A, Santos JC, Mishra BB, Jena P, Progida C, Sorensen OE, Gallo R, Appelberg R, Griffiths G. 2011. Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages. Cell Microbiol 13: 1601–1617. http://dx.doi.org/10.1111/j.1462-5822.2011.01644.x.
69. Rivas-Santiago B, Rivas Santiago CE, Castañeda-Delgado JE, León- Contreras JC, Hancock RE, Hernandez-Pando R. 2013. Activity of LL- 37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Agents 41: 143–148. http://dx.doi.org/10.1016/j.ijantimicag.2012.09.015.
70. Martineau AR, Nhamoyebonde S, Oni T, Rangaka MX, Marais S, Bangani N, Tsekela R, Bashe L, de Azevedo V, Caldwell J, Venton TR, Timms PM, Wilkinson KA, Wilkinson RJ. 2011. Reciprocal seasonal variation in vitaminDstatus and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A 108:19013–19017. http://dx.doi.org/10.1073/pnas.1111825108.
71. Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ, Rainbow SJ, Berry JL, Griffiths CJ. 2007. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 176: 208–213. http://dx.doi.org/10.1164/rccm.200701-007OC.
72. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S, Lee HM, Krutzik SR, Schenk M, Sieling PA, Teles R, Montoya D, Iyer SS, Bruns H, Lewinsohn DM, Hollis BW, Hewison M, Adams JS, Steinmeyer A, Zügel U, Cheng G, Jo EK, Bloom BR, Modlin RL. 2011. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 3:104ra102. http://dx.doi.org/10.1126/scitranslmed.3003045.
73. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, Timms PM, Venton TR, Bothamley GH, Packe GE, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Mein CA, Bhaw-Rosun L, Nuamah R, Young DB, Drobniewski FA, Griffiths CJ, Martineau AR. 2012. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A 109: 15449–15454. http://dx.doi.org/10.1073/pnas.1200072109.
74. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, Davidson RN, Sørensen OE, Kampmann B, Griffiths CJ, Wilkinson RJ. 2007. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 178:7190–7198. http://dx.doi.org/10.4049/jimmunol.178.11.7190.
75. Liu PT, Stenger S, Tang DH, Modlin RL. 2007. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 179: 2060–2063. http://dx.doi.org/10.4049/jimmunol.179.4.2060.
76. Chan J, Mehta S, Bharrhan S, Chen Y, Achkar JM, Casadevall A, Flynn J. 2014. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Semin Immunol 26:588–600. http://dx.doi.org/10.1016/j.smim.2014.10.005.
77. Achkar JM, Chan J, Casadevall A. 2015. B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev 264: 167–181. http://dx.doi.org/10.1111/imr.12276.
78. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, Mohaideen N, Ioerger TR, Sacchettini JC, Lipsitch M, Flynn JL, Fortune SM. 2011. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 43: 482–486. http://dx.doi.org/10.1038/ng.811.
79. Vandiviere HM, Loring WE, Melvin I, Willis S. 1956. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. AmJ Med Sci 232:30–37. http://dx.doi.org/10.1097/00000441-195607000-00006.
80. Coleman MT, Chen RY, Lee M, Lin PL, Dodd LE, Maiello P, Via LE, Kim Y, Marriner G, Dartois V, Scanga C, Janssen C, Wang J, Klein E, Cho SN, Barry CE, III, Flynn JL. 2014. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med 6:265ra167. http://dx.doi.org/10.1126/scitranslmed.3009500.
81. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944–1946. http://dx.doi.org/10.1126/science.1124410.
82. Manca C, Reed MB, Freeman S, Mathema B, Kreiswirth B, Barry CE, III, Kaplan G. 2004. Differential monocyte activation underlies strainspecific Mycobacterium tuberculosis pathogenesis. Infect Immun 72: 5511–5514. http://dx.doi.org/10.1128/IAI.72.9.5511-5514.2004.
83. López B, Aguilar D, Orozco H, Burger M, Espitia C, Ritacco V, Barrera L, Kremer K, Hernandez-Pando R, Huygen K, van Soolingen D. 2003. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 133: 30–37. http://dx.doi.org/10.1046/j.1365-2249.2003.02171.x.
84. Dormans J, Burger M, Aguilar D, Hernandez-Pando R, Kremer K, Roholl P, Arend SM, van Soolingen D. 2004. Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a BALB/c mouse model. Clin Exp Immunol 137:460–468. http://dx.doi.org/10.1111/j.1365-2249.2004.02551.x.
85. Portevin D, Gagneux S, Comas I, Young D. 2011. Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog 7:e1001307. http://dx.doi.org/10.1371/journal.ppat.1001307.
86. Reed MB, Domenech P, Manca C, Su H, Barczak AK, Kreiswirth BN, Kaplan G, Barry CE, III. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84–87. doi http://dx.doi.org/10.1038/nature02837.
87. Cambier CJ, Takaki KK, Larson RP, Hernandez RE, Tobin DM, Urdahl KB, Cosma CL, Ramakrishnan L. 2014. Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. Nature 505:218–222. http://dx.doi.org/10.1038/nature12799.
88. Lee W, VanderVen BC, Fahey RJ, Russell DG. 2013. Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J Biol Chem 288:6788-6800. http://dx.doi.org/10.1074/jbc.M112.445056.
89. Griffin JE, Pandey AK, Gilmore SA, Mizrahi V, McKinney JD, Bertozzi CR, Sassetti CM. 2012. Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations. Chem Biol 19: 218–227. http://dx.doi.org/10.1016/j.chembiol.2011.12.016.
90. Cox JS, Chen B, McNeil M, Jacobs WR, Jr. 1999. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402:79–83. http://dx.doi.org/10.1038/47042.
91. Sassetti CM, Rubin EJ. 2003. Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A 100:12989–12994. http://dx.doi.org/10.1073/pnas.2134250100.